Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Vogler

Showing results (141-150 of 184) with videos related to

Pageof 19
Sort By:
Cancer Research|May 15, 1990
Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analoguesB Zheng, K Oishi, M Shoji, et al.
British Journal of Haematology|July 1, 1990
MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemiaH Sato, H Preisler, R Day, et al.
Cancer Research|February 15, 1988
Influence of 1-beta-D-arabinofuranosylcytosine conjugates of lipids on the growth and metastasis of Lewis lung carcinomaW E Berdel, S Danhauser, C I Hong, et al.
Progress in Clinical and Biological Research|January 1, 1982
Influence of quantity of granulocytes transfused on responseE F Winton, S Moffitt, W R Vogler, et al.
The Journal of Biological Chemistry|April 22, 1994
Human leukemia K562 cell mutant (K562/OA200) selected for resistance to okadaic acid (protein phosphatase inhibitor) lacks protein kinase C-epsilon, exhibits multidrug resistance phenotype, and expresses drug pump P-glycoproteinB Zheng, T C Chambers, R L Raynor, et al.
American Journal of Hematology|August 1, 1993
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup studyJ Goldberg, J Gryn, A Raza, et al.
Experimental Hematology|November 1, 1992
Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup studyA Raza, S Gezer, J Anderson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemiaH D Preisler, A Raza, R Larson, et al.
Leukemia Research|March 1, 1994
Effect of herbimycin A, an inhibitor of tyrosine kinase, on protein tyrosine kinase activity and phosphotyrosyl proteins of Ph1-positive leukemia cellsM Okabe, K Kawamura, T Miyagishima, et al.
Leukemia|October 1, 1992
Phase II clinical trial of carboplatin in relapsed and refractory leukemiaW R Vogler, D P Harrington, E F Winton, et al.
Pageof 19

Showing results (141-150 of 184) with videos related to

Sort By:
Pageof 19
Cancer Research|May 15, 1990
Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analoguesB Zheng, K Oishi, M Shoji, et al.
British Journal of Haematology|July 1, 1990
MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemiaH Sato, H Preisler, R Day, et al.
Cancer Research|February 15, 1988
Influence of 1-beta-D-arabinofuranosylcytosine conjugates of lipids on the growth and metastasis of Lewis lung carcinomaW E Berdel, S Danhauser, C I Hong, et al.
Progress in Clinical and Biological Research|January 1, 1982
Influence of quantity of granulocytes transfused on responseE F Winton, S Moffitt, W R Vogler, et al.
The Journal of Biological Chemistry|April 22, 1994
Human leukemia K562 cell mutant (K562/OA200) selected for resistance to okadaic acid (protein phosphatase inhibitor) lacks protein kinase C-epsilon, exhibits multidrug resistance phenotype, and expresses drug pump P-glycoproteinB Zheng, T C Chambers, R L Raynor, et al.
American Journal of Hematology|August 1, 1993
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup studyJ Goldberg, J Gryn, A Raza, et al.
Experimental Hematology|November 1, 1992
Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup studyA Raza, S Gezer, J Anderson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemiaH D Preisler, A Raza, R Larson, et al.
Leukemia Research|March 1, 1994
Effect of herbimycin A, an inhibitor of tyrosine kinase, on protein tyrosine kinase activity and phosphotyrosyl proteins of Ph1-positive leukemia cellsM Okabe, K Kawamura, T Miyagishima, et al.
Leukemia|October 1, 1992
Phase II clinical trial of carboplatin in relapsed and refractory leukemiaW R Vogler, D P Harrington, E F Winton, et al.
Pageof 19